{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Sodium-Glucose Cotransporter 2 Inhibitors and Fournier Gangrene: A Rare and Lethal Adverse Event

Activity Steps

Purpose of Activity

To provide information on Fournier gangrene (FG) associated with sodium-glucose cotransporter 2 (SGLT2) inhibitors.

Learning Objectives/Outcomes

After completing this continuing education activity you will be able to:

  1. Summarize the epidemiology and potential benefits of the use of SGLT2 inhibitors.
  2. Identify potential adverse effects of SGLT2 inhibitors, including the signs and symptoms and treatment of FG.
Price: $12.95


  • ANCC 1.0 CH / 1.0 APH
  • DC - BON 1.0 CH
  • FL - BON 1.0 CH
  • GA - BON 1.0 CH

Lippincott Professional Development is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. This activity is also provider approved by the California Board of Registered Nursing, Provider Number CEP 11749. Lippincott Professional Development is also an approved provider of continuing nursing education by the District of Columbia Board of Nursing, Florida Board of Nursing, and Georgia Board of Nursing, #50-1223.

Awarded Advanced Pharmacology Hours

Test Code: CNS0319
Published: Mar/Apr
Expires: 3/5/2021
Required Passing Score: 13/18 (72%)
Authors: Patricia Anne O'Malley, PhD, APRN-CNS, CCRN Alumnus